Ionis Pharmaceuticals Inc. announced key business achievements and provided updates on its 2025 performance as well as milestones anticipated in 2026. In 2025, Ionis executed its first two independent product launches as a commercial-stage biotech company. For 2026, the company expects two additional independent launches: olezarsen for severe hypertriglyceridemia, marking Ionis' first entry into a large patient population, and zilganersen for Alexander disease, the first independent launch from its neurology pipeline. Ionis plans to submit a New Drug Application (NDA) for olezarsen in the first quarter of 2026, following its receipt of Breakthrough Therapy Designation, and anticipates launching the product later in the year. The company also reported ongoing enrollment in the Phase 3 REVEAL study of ION582 for Angelman syndrome, with enrollment completion expected in 2026 and data in 2027. Multiple Phase 2 data readouts from the neurology pipeline are expected. In its partnered programs, Ionis highlighted potential approval and launch of bepirovirsen for chronic hepatitis B (in partnership with GSK), with global regulatory submissions planned for 2026 following positive Phase 3 results. Results from the Phase 3 Lp(a) HORIZON study of pelacarsen for cardiovascular disease (in partnership with Novartis) are expected in the first half of 2026, with a planned NDA submission. Ionis stated it anticipates five Phase 3 readouts and four NDA submissions in 2026, and projects accelerating revenue growth to achieve cash flow breakeven in 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260111381308) on January 12, 2026, and is solely responsible for the information contained therein.
Comments